Showing 5531-5540 of 7866 results for "".
- Study Links Psoriasis to NMSC in Womenhttps://practicaldermatology.com/news/study-links-psoriasis-nmsc-women/2468243/Psoriasis was associated with a higher risk of nonmelanoma skin cancer in women in a new study published in Nature Communications. “An observational and genetic investigation into the association between psoriasis and risk of malignancy” found higher risks of a total of 16 types of cancer
- Study: Adherence Declines With Complex Atopic Dermatitis Regimenshttps://practicaldermatology.com/news/dherence-declines-complex-atopic-dermatitis-regimens-aad-guidelines/2468194/New American Academy of Dermatology (AAD) guidelines emphasize complex topical regimens for atopic dermatitis (AD), but adherence issues may limit their effectiveness, according to new research. According to a recent article in the Journal of Drugs in Dermatology, the AAD released
- ASDS Hosts New 'Expertise Summit'https://practicaldermatology.com/news/asds-hosts-new-expertise-summit/2468191/More than 50 dermatologic surgeons and dermatology residents gathered in Chicago, Illinois, on September 7-8 for a new course from the American Society for Dermatologic Surgery (ASDS), titled “ASDS Expertise Summit: Surgery. Injectables.” Practical Dermatology Editorial Board member Dr. As
- Lebrikizumab Gains FDA Approval for ADhttps://practicaldermatology.com/news/lebrikizumab-gains-fda-approval-ad/2468189/The targeted IL-13 inhibitor lebrikizumab was approved by the US Food and Drug Administration for the treatment of adults and children 12 and older who weigh at least 88 lbs with moderate-to-severe atopic dermatitis that is not well controlled despite treatment with topical prescription therapies
- Tralokinumab Safe for Special Atopic Dermatitis Populationshttps://practicaldermatology.com/news/tralokinumab-found-safe-special-ad-populations/2468141/A recent retrospective study indicated that tralokinumab was linked with significant improvements in atopic dermatitis (AD) in special populations (SPs) such as the elderly and those with significant comorbidities. Researchers investigating the efficacy and safe
- Study: Melanoma Declining Among Ages 30-59 in Swedenhttps://practicaldermatology.com/news/study-melanoma-declining-among-ages-30-59-sweden/2468114/Melanoma incidence and mortality rates have declined in recent years among 30- to 59-year-olds in Sweden, according to a recent study published in JAMA Dermatology. A cohort study involving Sweden’s entire population found a continuous rise in primary invasive cutaneous melanoma incidence
- Report: Global Skin Cancer Treatment Market to Hit $14.5 Billion by 2031https://practicaldermatology.com/news/global-skin-cancer-treatment-market-poised-rapid-growth-expected-hit-145-billion-2031/2468065/A recent report from Allied Analytics said the global skin cancer treatment market is projected to nearly double, reaching $14.5 billion by 2031, driven by an increasing incidence of skin cancer and advancements in treatment options. The $7.2 billion (2021) treatment market, according to t
- Analysis: COX1 Genotype Determines Fish Oil’s Efficacy Against ADhttps://practicaldermatology.com/news/analysis-cox1-genotype-determines-fish-oils-efficacy-against-ad/2467997/A secondary analysis of a randomized clinical trial indicated prenatal ω-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) supplementation may reduce the risk of childhood atopic dermatitis (AD) in a genotype-specific manner. Researchers for the analysis reported that mothers carrying t
- Two New Options for After-Sun Care Launchedhttps://practicaldermatology.com/news/two-new-options-after-sun-care-launched/2467968/San Diego-based skincare company Terns announced today that it has launched two new after-sun care products targeting outdoor enthusiasts. The products, which include a range of creams and gels, are formulated with the proprietary Sirenas Complex, which the manufacturer said is derived f
- Study Analyzes Genes Targeted by NB-UVB for Atopic Dermatitishttps://practicaldermatology.com/news/study-analyzes-genes-targeted-nb-uvb-ad/2467966/Applied narrowband ultraviolet B (NB-UVB) radiation is likely a suitable therapeutic method for atopic dermatitis, according to a network analysis in the Journal of Lasers in Medical Sciences. The study, undertaken by researchers in Iran, aimed to explore the critical genes that are target